Physician profile
Gary J Barrett
NPI 1578571592
$2,156.79
in general payments reported to CMS, 2019-2025
29 companies · $887 in 2025
The $887 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $38.93 · 2021: $31.89 · 2022: $275 · 2023: $183 · 2024: $558 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.21 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $246.94 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $244.84 | 2022-2025 | Repatha, Otezla, Otezla |
| Calliditas Therapeutics US INC. | $209.08 | 2024-2025 | Tarpeyo |
| Novo Nordisk INC | $207.01 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $92.11 | 2019-2025 | |
| Exact Sciences Corporation | $87.19 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $80.29 | 2019-2024 | |
| Glaxosmithkline, LLC. | $73.63 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.53 | 2024-2025 | Caplyta |
| Ani Pharmaceuticals, INC. | $67.89 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.23 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $44.88 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $41.65 | 2024 | Acthar |
| Amarin Pharma, INC. | $40.57 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $39.39 | 2025 | Korlym |
| Travere Therapeutics, INC. | $39.05 | 2025 | |
| Lilly USA, LLC | $37.15 | 2025 | Jardiance, Mounjaro |
| Dexcom, INC. | $24.96 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $23.92 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $23.48 | 2023 | Yupelri |
| Phadia US INC. | $23.39 | 2025 | Immunocap |
| Ardelyx, INC. | $21.08 | 2024 | Ibsrela |
| Philips North America LLC | $19.42 | 2025 | Ecc Solutions |
| Vifor Pharma, INC. | $18.35 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.12 | 2025 | Empaveli |
| Phathom Pharmaceuticals, INC. | $16.55 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $16.08 | 2022 | |
| Shire North American Group INC | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.